Clinical Trial Update: Study of Abemaciclib in Dedifferentiated Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 study of abemaciclib in dedifferentiated liposarcoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Sarcoma

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Dedifferentiated Liposarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING